The present study aimed to observe the synergistic effect of Astragalus flavonoids (TFA) on breast cancer chemotherapeutic agent cyclophosphamide (CTX) and its effect on immunologic function. 4T1 breast cancer bearing mice were established and then randomly into control group, model group, CTX group (80 mg/kg), CTX (80 mg/kg) combined with TFA (6 mg/kg) group and TFA group (6 mg/ kg). After 3 weeks of different treatments, tumor inhibition rates were measured; subpopulation of the splenic lymphocytes and marrow derived suppressor cells (MDSCs) E-mail: ygm@mail.sysu.edu.cn Glioblastoma (GBM) is among the most aggressive of human cancers. Although differentiation therapy has been proposed as a potential approach to treat GBM, the mechanisms of induced differentiation remain poorly defined. Here, we established an induced differentiation model of GBM using cAMP activators, which specifically directed GBM into astroglia. Next, transcriptomic and proteomic analyses uncovered oxidative phosphorylation and mitochondrial biogenesis were involved in induced differentiation of GBM. Further investigation showed dbcAMP reversed the Warburg effect evidenced by increase in oxygen consumption and reduction of lactate production. Stimulated mitochondrial biogenesis downstream of CREB/PGC1α pathway triggered metabolic shift and differentiation. Blocking mitochondrial biogenesis by mdivi1 or silencing PGC1α abrogated differentiation, reversely overexpression of PGC1α elicited differentiation. In GBM xenograft models and patient-derived GBM samples, cAMP activators also induced tumor growth inhibition and differentiation. This study shows mitochondrial biogenesis and metabolic switch to oxidative phosphorylation drive the differentiation process of tumor cells. Keywords: differentiation therapy; metabolic reprogramming; Warburg effect; PGC-1 alpha; mitochondrial biogenesis Acknowledgements: This work was supported by grants from the the National Natural Science Foundation of China (No 81673447), the Natural Science Foundation of Guangdong Province, China (No 2014A030313156) and the specific project of science and technology of Guangzhou (No 201607010396).
The resistance mechanisms that limit the efficacy of retinoid therapy in cancer are poorly understood. Sphingosine kinase 2 (SphK2) is a highly conserved enzyme that is mainly located in the nucleus and endoplasmic reticulum. Unlike well-studied sphingosine kinase 1 (SphK1) located in the cytosol, little has yet understood the functions of SphK2. Here we show that SphK2 over-expression contributes to the resistance of all-trans retinoic acid (ATRA) therapy in colon cancer through rapid degradation of cytoplasmic retinoid X receptor α (RXRα) by lysine 48 (K48)-and lysine 63 (K63)-based polyubiquitination. Human colonic adenocarcinoma HCT-116 cells transfected with SphK2 Sphk2 cells) demonstrate resistance to ATRA therapy as determined by in vitro and in vivo assays. Sphk2 over-expression increases the ATRA-induced nuclear RXRα export to cytoplasm and then rapidly degrades RXRα through the poly-ubiquitination pathway. We further show that Sphk2 activates the ubiquitin-proteasome system through the signal mechanisms of (1) K48-linked proteosomal degradation and (2) K63-linked ubiquitin-dependent autophagic degradation. These results provide new insights into the biological functions of Sphk2 and the molecular mechanisms that underlie the Sphk2-mediated resistance to retinoid therapy. Keywords: sphingosine kinase 2 (SphK2); retinoid therapy resistance; cytoplasmic RXRα; polyubiquitination; rapid degradation; lysine 48 (K48); lysine 63 (K63)orally once a day for 12 consecutive weeks. APC Min/+ mice fed with myricetin developed fewer and smaller polyps without any adverse effects. Histopathological analysis showed a decreased number of dysplastic cells and degree of dysplasia in each polyp. Immunohistochemical and Western blot analysis revealed that myricetin selectively inhibits cell proliferation and induces apoptosis in adenomatous polyps. The effects of myricetin were associated with a modulation the GSK-3β and Wnt/β-catenin pathways. ELISA analysis showed a reduced concentration of pro-inflammatory cytokines IL-1β, IL-6, TNF-α, and PGE 2 in the adenomatous polyps and blood, which were elevated in APC Min/+ mice. The effect of myricetin treatment was most prominent in the adenomatous polyps originating in the colon. Further study showed that myricetin down-regulates the phosphorylated p38 MAPK/Akt/mTOR signaling pathways, which may be the mechanisms for the inhibition of adenomatous polyps by myricetin. Taken together, our data show that myricetin inhibits intestinal tumorigenesis through a collection of biological activities. Given these results, we suggest that myricetin could be used preventatively to reduce the risk of developing colon cancers. E-mail: jiangwg@gmail.com Gastric cancer is one of the most common cancers in Asian countries and is the fourth most commonly occurring cancer worldwide. In the past decade, numerous groups have attempted to profile the expression changes in gastric cancer tissues using proteomic approaches, in search of diagnostic and prognostic biomarkers. However, investigating signalling network with proteomics approach is rarely reported. In this study, we aimed to investigate the PDGFB regulation network in gastric cancer with a label free proteomics approach. To validate the network, the PDGFB was silenced in gastric cancer cells with shRNA based approach. The predicted proteins were validated with Western blot in the PDGFB knockdown cells. To evaluate the effect of PDGFB on gastric cancer cells, cell proliferation was measured in PDGFB knockdown cells. In our study, a total of 2280 unique proteins were identified. Among these, 87 were potentially differentially expressed between gastric cancer and normal gastric tissues. Gastric cancer tissues had an obvious up-regulation of PRDX5, CALR, and CTSD, and a marked down-regulation of S100A6. Furthermore, by applying novel pathway analysis, we found upstream regulators including PDGF-B, PDGFR-β, Akt, eIF4E and p70s6K were obviously increased in the gastric cancer tissues. In addition, silencing of PRDX5 and PDGF-B expression suppressed the proliferation properties of gastric cancer cells in vitro.
The exogenous PDGF-BB could recover the reduced proteins expression of PDGF-B signaling pathway as PDGF-B knockdown. Our studies suggested that PDGF-B signaling pathway plays an important role in the regulation of gastric cancer proliferation and may be a reasonable approach for treatment of gastric cancer. It is demonstrated that breast cancer cells secrete DJ-1. However, the physiological and pathological significance of DJ-1 secretion is not clearly understood. In fact, a high level of DJ-1 protein has been detected in peripheral blood of patients with breast cancers, which could be a biomarker candidate for breast cancer. We previously found that NRG-1 promoted the decoupling of DJ-I with HER3 and activated the heterodimerization of HER2/HER3. In this study, we found that the detectable DJ-1 protein expression is decreased, but the HER3 expression is increased, in tumor tissue with the progression of breast cancer disease. There is a significant rise of DJ-1 in the supernatant of MCF-7 cells and in serum in vitro after stimulation of NRG-1 in the normal control. Furthermore, we found that the level of DJ-1 in supernatant or serum of HER3 knockdown group was not detected both with and without NRG-1. While DJ-1 level in supernatant or serum of HER3 overexpression group increased significantly than that in normal group with NRG-1 stimulation. These results suggest that NRG-1 improve the exocrine of DJ-1 protein, which was significantly affected by HER3 level in vivo and in vitro. Moreover, our findings indicate that serum DJ-1 level is a potential serum biomarker for predicting HER3-positive breast cancer patients. Keywords: serum DJ-1; HER3; NRG-1; breast cancers; MCF-7 cells Acknowledgements: This work was sponsored by the National Natural Science Foundation of China (No 81102422, 81373398); a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).
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Plk1 promotes esophageal squamous cell carcinoma cell metastasis by increasing YAP Ji-ming LING, Xiao-lin XU, Ji-yu JU, Wei GAO, Chun-ling ZHAO * Weifang Medical University, Weifang 261042, China * To whom correspondence should be addressed. E-mail: zhaochunlingbj@163.com Polo-like kinase 1(Plk1), a key regkulator of cell cycle progression, is over-expressed in most cancers and can promote proliferation and metastasis. The present study aimed to investigate the function of Plk1 in esophageal squamous cell carcinoma (ESCC) cells metastasis and its potential mechanism. Cell migratory and invasive capabilities were examined by wound scratch assay and Matrigel assay in Eca-109 cells transfected with siPlk1. The pulmonary metastasis model in nude mice were established and treated with siPlk1. The lung metastatic nodules were counted. Immunofluorescence staining and immunoblot were used to explore the expression of E-cadherin, vimentin and Snail. And E-cadherin in the lung metastatic nodules was examined by immunohistochemistry. Expression of total YAP and nuclear YAP were examined by immunoblot. Transcription of CTGF and LYP were also examined by real-time RT-PCR. TE-8 cells were transfected with Plk1 expression plasmid or a combination of Plk1 expression plasmid and siYAP. Cell migratory and invasive capabilities were examined by Transwell assay and Marigel invasion assay. Expression of E-cadherin, vimentin and Snail were examined by immunoblot. Knockdown of Plk1 reduces migratory and invasive capability of ESCC cell lines in in vitro or in vivo. Loss of Plk1 converts ESCC cell from a mesenchymal phenotype to epithelial phenotype. Reduction of Plk1 results in decrease of total and nuclear Yes-associated protein (YAP), and reduces the transcription of YAP target genes, CTGF and LYP. Furthermore, knockdown of YAP substantially abolishes Plk1 over-expression-induced migration and invasion as well as mesenchymal cell phenotype. In total, Plk1 plays an important role in ESCC development, and might be a potential therapeutic target for ESCC metastasis. Keywords: PLK; esophageal squamous cell carcinoma; metastasis; YAPSection 3: Anti-tumor pharmacology be attributed to the lack of effective treatment; the currently used chemotherapeutic agent temozolomide is non-specific, highly cytotoxic, and ineffective. There is an urgent need for new therapeutic agents, which first requires the identification of effective drug targets. TRPM7 aberrant expression has been strongly linked with promoting GBM cellular functions. We previously reported that TRPM7 inhibition suppressed GBM cellular functions.
The aim of this study is to evaluate TRPM7 as a drug target for GBM treatment by potentiating TRPM7 with the recently discovered agonist (naltriben), and examining outcomes of GBM cellular functions (proliferation, migration, and invasion).
With patch-clamp electrophysiology, we observed in the human GBM cell line U87 that naltriben further potentiated the endogenous TRPM7 current. Next, with Fura-2 calcium imaging, we found that there was robust calcium influx in response to naltriben perfusion. GBM cellular functions were then examined with the MTT assay, scratch wound assay, and Matrigel Transwell assay (to assess proliferation, migration, and invasion, respectively). We found that naltriben significantly enhanced U87 migration and invasion, but not proliferation. To examine the underlying mechanism, we employed Western immunoblotting to detect the protein levels of p-Akt/t-Akt, and p-ERK1|2/t-ERK1|2. Naltriben-application significantly upregulated ERK signaling, but not Akt signaling.
The current study verifies the involvement of TRPM7 in GBM cellular functions, and provides evidence that TRPM7 activity can potentially be further augmented even in GBM. Treatment options for GBM patients should be considered cautiously in order not to upregulate TRPM7 activity. Keywords: glioblastoma; GBM; TRPM7; naltriben
